{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:35:28Z","timestamp":1789785328396,"version":"4.0.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.imlet.2015.06.017","type":"journal-article","created":{"date-parts":[[2015,8,7]],"date-time":"2015-08-07T23:52:26Z","timestamp":1438991546000},"page":"67-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["CD55, CD59, factor H and factor H-like 1 gene expression analysis in tumors of the ovary and corpus uteri origin"],"prefix":"10.1016","volume":"167","author":[{"given":"L.","family":"Kapka-Skrzypczak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Wolinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Szparecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.M.","family":"Wilczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Czajka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Skrzypczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.imlet.2015.06.017_bib0005","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012","volume":"49","author":"Ferlay","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.imlet.2015.06.017_bib0010","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.imlet.2015.06.017_bib0015","first-page":"1","article-title":"Human protectin (CD59), an 18,000\u201320,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers","volume":"71","author":"Meri","year":"1990","journal-title":"Immunology"},{"key":"10.1016\/j.imlet.2015.06.017_bib0020","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.4049\/jimmunol.144.9.3478","article-title":"The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9","volume":"144","author":"Rollins","year":"1990","journal-title":"J. Immunol."},{"key":"10.1016\/j.imlet.2015.06.017_bib0025","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0161-5890(89)90097-7","article-title":"Characterization of a broadly expressed human leucocyte surface antigen MEM-43 anchored in membrane through phosphatidylinositol","volume":"26","author":"Stefanova","year":"1989","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.imlet.2015.06.017_bib0030","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1084\/jem.170.3.637","article-title":"CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells","volume":"170","author":"Davies","year":"1989","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.imlet.2015.06.017_bib0035","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0165-2478(93)90058-A","article-title":"Soluble CD59 in pregnancy and infancy","volume":"36","author":"Bjorge","year":"1993","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.imlet.2015.06.017_bib0040","first-page":"541","article-title":"Characterization of the membrane attack complex inhibitory protein CD59 antigen on human amniotic cells and in amniotic fluid","volume":"76","author":"Rooney","year":"1992","journal-title":"Immunology"},{"key":"10.1016\/j.imlet.2015.06.017_bib0045","doi-asserted-by":"crossref","first-page":"184","DOI":"10.4049\/jimmunol.129.1.184","article-title":"Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system","volume":"129","author":"Nicholson- Weller","year":"1982","journal-title":"J. Immunol."},{"key":"10.1016\/j.imlet.2015.06.017_bib0050","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1084\/jem.162.1.75","article-title":"Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria","volume":"162","author":"Kinoshita","year":"1985","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.imlet.2015.06.017_bib0055","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1084\/jem.165.3.848","article-title":"Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids","volume":"165","author":"Medof","year":"1987","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.imlet.2015.06.017_bib0060","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood.V65.5.1237.1237","article-title":"Surface membrane expression by human blood leukocytes and platelets of decay-accelerating factor, a regulatory protein of the complement system","volume":"65","author":"Nicholson-Weller","year":"1985","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2015.06.017_bib0065","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1084\/jem.163.1.221","article-title":"Decay-accelerating factor is present on cultured human umbilical vein endothelial cells","volume":"163","author":"Asch","year":"1986","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.imlet.2015.06.017_bib0070","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1084\/jem.165.6.1731","article-title":"The gene encoding decay-accelerating factor (DAF) is located in the complement-regulatory locus on the long arm of chromosome 1","volume":"165","author":"Lublin","year":"1987","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.imlet.2015.06.017_bib0075","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.4049\/jimmunol.156.7.2528","article-title":"Localization of classical and alternative pathway regulatory activity within the decay-accelerating factor","volume":"156","author":"Brodbeck","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/j.imlet.2015.06.017_bib0080","series-title":"LW. Immunologia","author":"Go\u0142\u0105b","year":"2002"},{"key":"10.1016\/j.imlet.2015.06.017_bib0085","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1084\/jem.146.1.257","article-title":"Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution","volume":"146","author":"Pangburn","year":"1977","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.imlet.2015.06.017_bib0090","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.it.2008.04.008","article-title":"Factor H Family proteins and human diseases","volume":"29","author":"Jozsi","year":"2008","journal-title":"Trends Immunol."},{"key":"10.1016\/j.imlet.2015.06.017_bib0095","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0162-3109(00)80300-8","article-title":"Host recognition and target differentiation by factor H, a regulator of the alternative pathway of complement","volume":"49","author":"Pangburn","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.imlet.2015.06.017_bib0100","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1040-8428(01)00130-5","article-title":"Rituximab: perspective on single agent experience, and future directions in combination trials","volume":"40","author":"McLaughlin","year":"2001","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.imlet.2015.06.017_bib0105","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1046\/j.1365-2249.2003.02066.x","article-title":"Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid","volume":"131","author":"Donin","year":"2003","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.imlet.2015.06.017_bib0110","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/(SICI)1097-0215(19970106)70:1<14::AID-IJC3>3.0.CO;2-9","article-title":"Complement-regulatory proteins in ovarian malignancies","volume":"70","author":"Bjorge","year":"1997","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.imlet.2015.06.017_bib0115","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nri2744","article-title":"Monoclonal antibodies: versatile platforms for cancer immunotherapy","volume":"10","author":"Weiner","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.imlet.2015.06.017_bib0120","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0167-5699(99)01537-6","article-title":"Immune evasion of tumor cells using membrane-bound complement regulatory proteins","volume":"20","author":"Gorter","year":"1999","journal-title":"Immunol. Today"},{"key":"10.1016\/j.imlet.2015.06.017_bib0125","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0161-5890(03)00112-3","article-title":"Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors","volume":"40","author":"Fishelson","year":"2003","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.imlet.2015.06.017_bib0130","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/(SICI)1096-9098(199703)64:3<222::AID-JSO9>3.0.CO;2-C","article-title":"Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A","volume":"64","author":"Juhl","year":"1997","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.imlet.2015.06.017_bib0135","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1586\/14737140.5.1.87","article-title":"Monoclonal antibody therapy of ovarian cancer","volume":"5","author":"Nicodemus","year":"2005","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.imlet.2015.06.017_bib0140","article-title":"Toll-like receptors in ovarian as targets for immunotherapies","volume":"5","author":"Muccioli","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.imlet.2015.06.017_bib0145","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ygyno.2014.03.553","article-title":"B7-H4 as a potential target for immunotherapy for gynecologic cancers: a closer look","volume":"134","author":"Smith","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.imlet.2015.06.017_bib0150","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40291-013-0024-9","article-title":"HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies","volume":"17","author":"English","year":"2013","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.imlet.2015.06.017_bib0155","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-3083.2006.01751.x","article-title":"Minimal residual disease in ovarian cancer as a target for complement-mediated mAb immunotherapy","volume":"63","author":"Bjorge","year":"2006","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.imlet.2015.06.017_bib0160","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.molonc.2013.02.011","article-title":"Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab","volume":"7","author":"Mamidi","year":"2013","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.imlet.2015.06.017_bib0165","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.3324\/haematol.2013.089615","article-title":"Complement factor H-derived short consensus repeat 18\u201320 enhanced complement-dependent cytotoxicity of ofatumumab on chronic lymphocytic leukemia cells","volume":"98","author":"Horl","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.imlet.2015.06.017_bib0170","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1038\/leu.2013.169","article-title":"Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity","volume":"27","author":"Horl","year":"2013","journal-title":"Leukemia"}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247815300043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247815300043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T23:52:23Z","timestamp":1691884343000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165247815300043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0165247815300043"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2015.06.017","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD55, CD59, factor H and factor H-like 1 gene expression analysis in tumors of the ovary and corpus uteri origin","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2015.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}